Phase 2
Completed N=50
ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
Source: ClinicalTrials.gov NCT00934050 ↗Enrolled (actual)
50
Serious AEs
14.6%
Results posted
May 2015
Primary outcomePrimary: Treatment Emergent Adverse Events (TEAEs) — 21; 23 participants
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of ELND005 beyond the 18 months of treatment in original randomized and blinded clinical trail ELND005-AD201.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Treatment Emergent Adverse Events (TEAEs) |
21; 23 | — |
Eligibility Criteria
Inclusion Criteria
- This study is open only to subjects who have completed the week 78 visit in Study ELND005-AD201 while taking their assigned dose of study drug medication.
Exclusion Criteria
- Subject has no new medical contraindications to continued participation in the study.
Data sourced from ClinicalTrials.gov (NCT00934050). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.